Giovanni Caforio, Bristol Myers Squibb CEO (Nicolas Messyasz/Sipa via AP Images)
BMS looks to new product portfolio as revenues slide due to Revlimid losses
Bristol Myers Squibb cited lower Revlimid sales as a driver of its falling revenue in the US in the second quarter of 2023.
The cancer …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
